Detection of Phospho-Sites Generated by Protein Kinase CK2 in CFTR: Mechanistic Aspects of Thr1471 Phosphorylation

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Venerando, Andrea ^a   Franchin, Cinzia ^a   Cant, Natasha ^b   Cozza, Giorgio ^a   Pagano, Mario A ^a   Tosoni, Kendra ^c   Al Zahrani, Ateeq ^b   Arrigoni, Giorgio ^a   Ford, Robert C ^b   Mehta, Anil ^c   Pinna, Lorenzo A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CASEIN KINASE I; CASEIN KINASE II; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; POLO LIKE KINASE 2; POLO LIKE KINASE 3; PROTEIN KINASE INHIBITOR; SERINE; THREONINE;

ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; CASEIN KINASE II; CELL LINE; CRICETINAE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; KINETICS; MASS SPECTROMETRY; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NAPHTHYRIDINES; PHOSPHOPEPTIDES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; SACCHAROMYCES CEREVISIAE; SERINE; THREONINE;

EID: 84884239437     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074232     Document Type: Article

References (45)

1. Pissarra LS, Farinha CM, Xu Z, Schmidt A, Thibodeau PH, et al. (2008) Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. Chem Biol 15: 62-69.
2. Schultz BD, Singh AK, Devor DC, Bridges RJ, (1999) Pharmacology of CFTR chloride channel activity. Physiol Rev 79: S109-144.
3. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, et al. (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83: 129-135.
4. Heda GD, Tanwani M, Marino CR, (2001) The Delta F508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am J Physiol, Cell Physiol 280: C166-174.
5. Neville DC, Rozanas CR, Price EM, Gruis DB, Verkman AS, et al. (1997) Evidence for phosphorylation of serine 753 in CFTR using a novel metal-ion affinity resin and matrix-assisted laser desorption mass spectrometry. Protein Sci 6: 2436-2445.
6. Csanády L, Seto-Young D, Chan KW, Cenciarelli C, Angel BB, et al. (2005) Preferential phosphorylation of R-domain Serine 768 dampens activation of CFTR channels by PKA. J Gen Physiol 125: 171-186.
7. McClure M, DeLucas LJ, Wilson L, Ray M, Rowe SM, et al. (2012) Purification of CFTR for mass spectrometry analysis: identification of palmitoylation and other post-translational modifications. Protein Eng Des Sel 25: 7-14.
8. Pinna LA, (2002) Protein kinase CK2: a challenge to canons. J Cell Sci 115: 3873-3878.
9. Pagano MA, Arrigoni G, Marin O, Sarno S, Meggio F, et al. (2008) Modulation of protein kinase CK2 activity by fragments of CFTR encompassing F508 may reflect functional links with cystic fibrosis pathogenesis. Biochemistry 47: 7925-7936.
10. Torres J, Pulido R, (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276: 993-998.
11. Kato T Jr, Delhase M, Hoffmann A, Karin M, (2003) CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell 12: 829-839.
12. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, et al. (2006) A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126: 269-283.
13. Luz S, Kongsuphol P, Mendes AI, Romeiras F, Sousa M, et al. (2011) Contribution of casein kinase 2 and spleen tyrosine kinase to CFTR trafficking and protein kinase A-induced activity. Mol Cell Biol 31: 4392-4404.
14. Tosoni K, Stobbart M, Cassidy DM, Venerando A, Pagano MA, et al. (2013) CFTR mutations altering CFTR fragmentation. Biochem J 449: 295-305.
15. Kopito RR, (1999) Biosynthesis and Degradation of CFTR. Physiol Rev 79: S167-S173.
16. Meacham GC, Lu Z, King S, Sorscher E, Tousson A, et al. (1999) The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J 18: 1492-1505.
17. Farinha CM, Amaral MD, (2005) Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol 25: 5242-5252.
18. Gentzsch M, Chang X-B, Cui L, Wu Y, Ozols VV, et al. (2004) Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. Mol Biol Cell 15: 2684-2696.
19. Peters KW, Qi J, Johnson JP, Watkins SC, Frizzell RA, (2001) Role of snare proteins in CFTR and ENaC trafficking. Pflugers Arch 443Suppl 1: S65-69.
20. O'Ryan L, Rimington T, Cant N, Ford RC, (2012) Expression and purification of the cystic fibrosis transmembrane conductance regulator protein in Saccharomyces cerevisiae. J Vis Exp. 61: e3860.
21. Venerando A, Marin O, Cozza G, Bustos VH, Sarno S, et al. (2010) Isoform specific phosphorylation of p53 by protein kinase CK1. Cell Mol Life Sci 67: 1105-1118.
22. Salvi M, Trashi E, Marin O, Negro A, Sarno S, et al. (2012) Superiority of PLK-2 as α-synuclein phosphorylating agent relies on unique specificity determinants. Biochem Biophys Res Commun 418: 156-160.
23. Carpino LA, Henklein P, Foxman BM, Abdelmoty I, Costisella B, et al. (2001) The solid state and solution structure of HAPyU. J Org Chem 66: 5245-5247.
24. Thingholm TE, Jørgensen TJD, Jensen ON, Larsen MR, (2006) Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat Protoc 1: 1929-1935.
25. Taus T, Köcher T, Pichler P, Paschke C, Schmidt A, et al. (2011) Universal and Confident Phosphorylation Site Localization Using phosphoRS. J Proteome Res 10: 5354-5362.
26. Schägger H, (2006) Tricine-SDS-PAGE. Nat Protoc 1: 16-22.
27. Rohl CA, Strauss CEM, Misura KMS, Baker D, (2004) Protein structure prediction using Rosetta. Meth Enzymol 383: 66-93.
28. Kozakov D, Brenke R, Comeau SR, Vajda S, (2006) PIPER: an FFT-based protein docking program with pairwise potentials. Proteins 65: 392-406.
29. Chen R, Li L, Weng Z, (2003) ZDOCK: An initial-stage protein-docking algorithm. Proteins: Structure, Function, and Bioinformatics 52: 80-87.
30. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
31. Hallows KR, Raghuram V, Kemp BE, Witters LA, Foskett JK, (2000) Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. J Clin Invest 105: 1711-1721.
32. Short DB, Trotter KW, Reczek D, Kreda SM, Bretscher A, et al. (1998) An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. J Biol Chem 273: 19797-19801.
33. Wang S, Raab RW, Schatz PJ, Guggino WB, Li M, (1998) Peptide binding consensus of the NHE-RF-PDZ1 domain matches the C-terminal sequence of cystic fibrosis transmembrane conductance regulator (CFTR). FEBS Lett 427: 103-108.
34. Ostedgaard LS, Randak C, Rokhlina T, Karp P, Vermeer D, et al. (2003) Effects of C-terminal deletions on cystic fibrosis transmembrane conductance regulator function in cystic fibrosis airway epithelia. Proc Natl Acad Sci USA 100: 1937-1942.
35. Tagliabracci VS, Engel JL, Wen J, Wiley SE, Worby CA, et al. (2012) Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science 336: 1150-1153.
36. Lolli G, Cozza G, Mazzorana M, Tibaldi E, Cesaro L, et al. (2012) Inhibition of Protein Kinase CK2 by Flavonoids and Tyrphostins. A Structural Insight. Biochemistry 51: 6097-6107.
37. Salvi M, Trashi E, Cozza G, Franchin C, Arrigoni G, et al. (2012) Investigation on PLK2 and PLK3 substrate recognition. Biochim Biophys Acta 1824: 1366-1373.
38. Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y, (2007) Pharmacological and Functional Comparison of the Polo-like Kinase Family: Insight into Inhibitor and Substrate Specificity. Biochemistry 46: 9551-9563.
39. Cheng J, Moyer BD, Milewski M, Loffing J, Ikeda M, et al. (2002) A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression. J Biol Chem 277: 3520-3529.
40. Ren A, Zhang W, Yarlagadda S, Sinha C, Arora K, et al. (2013) MAST205 Competes with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-associated Ligand for Binding to CFTR to Regulate CFTR-mediated Fluid Transport. J Biol Chem 288: 12325-12334.
41. Meggio F, Pinna LA, (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17: 349-368.
42. Chen EY, Clarke DM, (2002) The PEST sequence does not contribute to the stability of the cystic fibrosis transmembrane conductance regulator. BMC Biochem 3: 29.
43. Battistutta R, Cozza G, Pierre F, Papinutto E, Lolli G, et al. (2011) Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry 50: 8478-8488.
44. Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, et al. (2006) Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127: 803-815.
45. Venerando A, Pagano MA, Cozza G, Arrigoni G, Mehta A, Pinna LA, (2011) Subverted signalling by protein kinase CK2 in ΔF508 CFTR expressing cells. Poster presentation. FEBS Journal 278: 387.